MPV17

Across TCGA pan-cancer cohorts, MPV17 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MPV17 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MPV17 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MPV17 expression acts as an unfavorable survival marker, although some lineages such as OV and LSCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where MPV17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	All	0.570	0.960	<.001	54	view →
PDAC	DFS	Median	All	0.684	0.874	.003	19	view →
LUAD	OS	Tertile	II,III,IV	0.775	1.000	.013	6	view →
OV	DFS	Median	All	1.000	0.868	.042	4	view →
LSCC	DFS	Median	III,IV	0.815	0.491	.045	2	view →
HNSC	DFS	Quartile	III,IV	0.738	0.536	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MPV17–CCRCC (DFS)

Open the CCRCC breakdown →